NCT01373736Unknown3 期
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
适应症
相关药物
试验速览
- 阶段
- 3 期
- 试验地点
- 2
研究概览
简要总结
The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroendocrine tumors.
研究设计
- 研究类型
- Interventional
- 主要目的
- Diagnostic
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must have a clinical indication for 123I-MIBG imaging to evaluate for the presence, extent, or status of neuroendocrine tumors;
- •subjects must be able and willing to comply with study procedures.
排除标准
- •Subjects with history of renal insufficiency (serum creatinine level > 3.0 mg/dL [265 µmol/L]) and inability to be withdrawn from medications known to interfere with 123I-MIBG uptake;
- •Subjects unable to tolerate lying supine;
- •Subjects pregnant or breastfeeding, unless the information to be gained outweighs the possible hazardous effects of 123I-MIBG administration. Where the assessment of the risk/benefit ration suggests the use of 123I-MIBG in nursing mothers, the breastfeeding should be discontinued for at least 48 hours post-injection.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or NeuroblastomaPheochromocytomaNeuroblastomaNCT00126412GE Healthcare251
Enrolling By Invitation
4 期
MIBG in Aging and Neurologic DisordersLewy Body DiseaseMild Cognitive ImpairmentREM Sleep Behavior DisorderDementiaParkinsonismNCT05514106Mayo Clinic50
已完成
3 期
Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular DiseaseHeart Failure, CongestiveNCT00126425GE Healthcare587
已完成
3 期
Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular DiseaseHeart Failure, CongestiveNCT00126438GE Healthcare515
已完成
1 期
Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the BrainAlzheimer DiseaseNCT00287248Institute for Neurodegenerative Disorders38
